Compare WRAP & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WRAP | MXCT |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United States | United States |
| Employees | 25 | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.8M | 93.0M |
| IPO Year | 2017 | 2021 |
| Metric | WRAP | MXCT |
|---|---|---|
| Price | $1.45 | $1.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 186.3K | ★ 941.5K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $4,672,000.00 | ★ $33,026,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.66 | N/A |
| 52 Week Low | $1.20 | $0.64 |
| 52 Week High | $3.23 | $2.40 |
| Indicator | WRAP | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 45.44 | 66.10 |
| Support Level | $1.41 | $0.77 |
| Resistance Level | $1.60 | $1.16 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 14.56 | 74.73 |
Wrap Technologies Inc is a public safety technology and services company that delivers safe and effective policing solutions to law enforcement and security personnel. The firm develops policing solutions to law enforcement and security personnel. Its BolaWRAP 150 Remote Restraint device is a patented, hand-held tool that discharges a Kevlar cord to restrain noncompliant individuals from a range of 10-25 feet. The group operates in the Americas, Europe, the Middle East, Africa and the Asia Pacific.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.